Hepatic BSCL2 (Seipin) deficiency disrupts lipid droplet homeostasis and increases lipid metabolism via SCD1 activity

Mohamed Amine Lounis¹, Simon Lalonde¹, Sabri Ahmed Rial¹, Karl-F. Bergeron¹, Jessica C. Ralston², David M. Mutch², and Catherine Mounier¹

¹ BioMed Research Center, Biological Sciences Department, University of Quebec in Montreal (UQÀM), Montreal, Quebec, Canada
² Department of Human Health & Nutritional Sciences, University of Guelph, Guelph, Ontario, Canada

Running title: Hepatic Seipin depletion increases SCD1 activity and LD formation

Corresponding author: Prof. Catherine Mounier, Département des sciences biologiques et centre de recherche BioMed, Université du Québec à Montréal, Case Postale 8888, Succursale Centre-ville, Montréal, QC, H3C 3P8, Canada. Phone: 1 (514) 987-3000 extension 8912. Fax: 1 (514) 987-4647. E-mail: mounier.catherine@uqam.ca

Key words: BSCL2, Seipin, lipid droplets, SCD1, lipogenesis, fatty acid uptake, insulin sensitivity
Abstract

Berardinelli-Seip congenital lipodystrophy (BSCL) is an autosomal recessive disorder. The more severe form, designated BSCL2, arises due to mutations in the BSCL2 gene. Patients with BSCL2, as well as Bscl2<sup>−/−</sup> mice, have a near total absence of body fat, an organomegaly and develop metabolic disorders including insulin resistance and hepatic steatosis. The function of the Seipin (BSCL2) protein remains poorly understood. Several lines of evidence have indicated that Seipin may have distinct functions in adipose versus non-adipose cells. Here we present evidence that BSCL2/Bscl2 plays a role in lipid droplet (LD) biogenesis and homeostasis in primary and cultured hepatocytes. Our results show that decreasing BSCL2/Bscl2 expression in hepatocytes increases the number and size of LD, as well as the expression of genes implicated in their formation and stability. We also show that knocking down SCD1 expression reverses the phenotype associated with Seipin deficiency. Interestingly, BSCL2 knockdown induces SCD1 expression and activity, potentially leading to increased basal phosphorylation of proteins involved in the insulin signaling cascade, as well as further increasing fatty acid uptake and <i>de novo</i> lipogenesis. In conclusion, our results suggest that a hepatic BSCL2/Bscl2 deficiency induces the increase and expansion of LD, potentially via increased SCD1 activity.
Hepatic Seipin depletion increases SCD1 activity and LD formation

**Abbreviations**

Acetyl-CoA carboxylase (ACC)
1-acylglycerol-3-phosphate O-acyltransferases (AGPAT)
Adipose triglyceride lipase (ATGL)
activating transcription factor-6 (ATF6)
analysis of variance (ANOVA)
Berardinelli-Seip congenital lipodystrophy (BSCL)
bovine serum albumin (BSA)
cell death-inducing DFFA-like effector a (CIDEA)
cholesteryl esters (CE)
diacylglycerol (DAG)
double-stranded RNA-dependent protein kinase-like ER kinase (PERK)
endoplasmic reticulum (ER)
Fatty acid synthase (FAS)
Fond de Recherche du Québec-Nature et Technologie (FRQNT)
glucose-6-phosphatase catalytic subunit (G6pc)
glucokinase (Gck)
glucose-regulated protein 78 (GRP78)
glucose tolerance test (GTT)
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
hypoxanthine phosphoribosyltransferase 1 (HPRT1)
inositol-requiring transmembrane kinase and endonuclease 1a (IRE1a)
insulin receptor substrate (IRS)
insulin tolerance test (ITT)
knockout (KO)
lipid droplet (LD)
mechanistic target of rapamycin (mTOR)
monounsaturated fatty acids (MUFA)
National Science and Engineering Research Council of Canada (NSERC)
non-alcoholic steatohepatitis (NASH)
peroxisome proliferator activated receptor (PPAR)
Hepatic Seipin depletion increases SCD1 activity and LD formation

perilipin 5 (PLIN5)
Phosphoenolpyruvate carboxykinase (Pepeck)
phosphate-buffered saline (PBS)
phospholipids (PL)
saturated fatty acids (SFA)
Sterol regulatory element binding protein-1c (SREBP-1c)
stearyl-CoA desaturase 1 (SCD1)
triacylglycerol (TAG)
unesterified fatty acids (FFA)
unfolded protein response (UPR)
wildtype (WT)
**Introduction**

Berardinelli-Seip syndrome is an autosomal form of congenital generalized lipodystrophy [1] identified by Berardinelli [2] from Brazil and Seip from Scandinavia [3]. The most severe form of this disorder is Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2), which is due to a loss of function of the $BSCL2$ gene [4-6]. This disorder is characterized by generalized lipodystrophy, insulin resistance, hypertriglyceridemia and severe hepatic steatosis [4-6]. In order to understand the function of the Seipin (BSCL2) protein, several groups have generated $Bscl2$ knockout mice ($Bscl2^{-/-}$) [7-9]. Besides the generalized lipodystrophic phenotype, $Bscl2^{-/-}$ mice develop most of the metabolic complications observed in patients carrying $BSCL2$ null mutations. Organomegaly has been reported in two $Bscl2^{-/-}$ lines, with an increased size of liver, kidneys, intestine, epididymis, heart and spleen. $Bscl2^{-/-}$ mice also suffer from massive hepatic steatosis, a decrease in energy expenditure, hyperglycemia, severe glucose intolerance, and insulin resistance [7-9]. $Bscl2^{-/-}$ mice revealed a critical role for Seipin in adipocyte maturation [9, 10]. It appears that loss of $Bscl2$ does not inhibit adipogenesis, but rather abrogates triacylglycerol (TAG) synthesis, thereby preventing the full maturation of adipocytes and subsequently leading to lipodystrophy [11]. The role of Seipin in non-adipose tissues remains unclear. Humans carrying $BSCL2$ mutations, as well as $Bscl2^{-/-}$ mice, develop severe hepatic steatosis associated with hepatic failure. Ectopic storage of lipids in the form of intracellular droplets within hepatocytes induces lipotoxicity, which is associated with severe pathological conditions including insulin resistance, pancreatic β-cell failure and non-alcoholic steatohepatitis (NASH), as well as hepatic inflammation [12-14]. In the absence of a functional Seipin protein, hepatic steatosis may be a consequence of a cell-intrinsic effect or a cell-extrinsic effect such as the disappearance of adipose tissue [15]. $Bscl2$ deficiency also has an intriguing impact on insulin sensitivity. Two recently published studies based on insulin and glucose tolerance tests (ITT and GTT, respectively) demonstrated that $Bscl2^{-/-}$ mice are insulin resistant [7, 8]. In contrast, another group showed insulin hypersensitivity in fasting $Bscl2^{-/-}$ mice, suggesting that under specific conditions these mice are not insulin resistant [16].
TAG are stored in the cell within lipid droplets (LD). Several studies have provided evidence that Seipin plays an evolutionarily conserved role in the biogenesis of LD in various models and tissues, including LD formation and homeostasis [8, 17-22]. Fei and colleagues suggested that the absence of B scl2 increases the level of neutral lipids in yeast, leading to the formation of supersized LD [19, 23, 24]. Knocking down BSCL2 in HeLa and NIH/3T3 cells significantly increases TAG synthesis and storage in LD, whereas its over-expression has the opposite effect [25]. In the salivary gland of Drosophila, Seipin deficiency promotes the accumulation of LD by increasing diacylglycerol (DAG) and TAG synthesis and storage [26]. In hepatic AML-12 cells, the overexpression of B scl2 inhibits LD formation [27]. Hence, low Seipin levels are systematically associated with increased TAG synthesis and/or LD formation. However, the particular mechanism by which Seipin participates in LD biogenesis remains unclear.

LD formation begins within ER membrane leaflets [28, 29]. Recently, Seipin was hypothesized to be a central scaffold protein within the ER [30]. In adipocytes, Seipin interacts with the adaptor protein 14-3-3β and may influence cytoskeletal remodeling [31]. Seipin also interacts with SERCA, an ER Ca$^{2+}$-ATPase regulating lipid storage in adipocytes [32]. Finally, Talukder and collaborators demonstrated that Seipin can form a complex with AGPAT2 and LPIN1 (Lipin-1) to modulate ER-based lipogenesis and adipogenesis [30]. Several reports have implicated the disruption of ER homeostasis, or ER stress, in the development of hepatic steatosis [33-38]. Any event that leads to a disruption of ER homeostasis, such as excessive protein synthesis, an accumulation of misfolded protein or a change in calcium levels will induce an unfolded protein response (UPR) [38-40]. In mammalian cells, the UPR is mediated by three ER proteins: 1) the inositol-requiring transmembrane kinase and endonuclease 1a (IRE1a), 2) the double-stranded RNA (dsRNA)-dependent protein kinase-like ER kinase (PERK), and 3) the activating transcription factor-6 (ATF6) [41]. In physiologically normal conditions, these proteins are kept inactive through their association with the ER chaperone glucose-regulated protein 78 (GRP78)/ immunoglobulin-heavy-chain-binding protein. Following the induction of ER stress, GRP78 releases the three UPR proteins in order to manage the accumulation of unfolded proteins, resulting in the activation of PERK, IRE1a, and ATF6 [38].
The present study aimed to analyze the effect of Seipin deficiency on the formation and homeostasis of LD in cultured hepatocytes. *Bscl2/BSCL2* knockdown modified the quantity and morphology of LD, and affected their growth and aggregation. This was associated with an induction of SCD1 expression and activity, as reflected by an increase in the ratio of monounsaturated fatty acids to saturated fatty acids (MUFA/SFA). In these conditions, fatty acid uptake and *de novo* lipogenesis were also activated. In addition, we showed that lowering Seipin levels in hepatocytes increased basal phosphorylation of insulin signaling proteins. Our data also revealed that the Seipin deficiency phenotype could be reversed with a *SCD1* knockdown. Finally, concomitant to increased lipid storage, *BSCL2/Bscl2* knockdown triggered an activation of ER stress in hepatocytes.
Materials and Methods

Bscl2 knockout samples
Liver samples and whole cell extracts (mRNA and proteins) from Bscl2<sup>−/−</sup> mice were a generous gift from Dr. Jocelyne Magré (INSERM, University of Nantes, France) and Dr. Xiaoqin Ye (University of Georgia, USA). Mice were housed and monitored in accordance with protocols approved by their local animal care committees. Fasted (for 24h, beginning and ending in the morning, during the light period of the light/dark cycle) and non-fasted (fed) mice were used to test different physiological conditions (basal versus nutrient-rich, respectively) under a standard low fat diet [8].

Cell culture and transfection
Primary hepatocytes were isolated from 3-month-old (125g) male Sprague Dawley rats (Harlan Laboratories) using a collagenase perfusion protocol [42, 43]. Harvested hepatocytes were plated on collagen-coated 12-well plates in DMEM/F12 medium (1:1; Wisent) containing 10% fetal bovine serum (Hyclone Laboratories) and 1% penicillin-streptomycin-amphotericin B (Thermo Fisher Scientific). Following an overnight incubation (37°C, 5% CO<sub>2</sub>), cells were washed with 1x phosphate-buffered saline (PBS) and serum-free medium was added for 24h before further treatments. The University of Quebec at Montreal’s Animal Care Committee (CIPA) approved all experimental protocols.

HepG2 human hepatocyte cells (ATCC) were cultured in EMEM medium (Wisent) supplemented with 10% fetal bovine serum, 100U/ml penicillin and 100µg/ml streptomycin (Thermo Fisher Scientific). At confluence, serum-free medium without antibiotics was applied for 24h.

After 24h in serum-free medium, HepG2 cells and primary rat hepatocytes were transfected overnight using the DharmaFECT4 reagent with either negative control No. 1 (CTRL), BSCL2 and/or SCD1 (in HepG2 cells), or Bscl2 (in primary rat hepatocytes) Silencer Select siRNA(s) according to the manufacturer’s instructions (#4390843,
Hepatic Seipin depletion increases SCD1 activity and LD formation

The next day, cells were treated for 24h with 100µM oleate (2 mol/mol BSA; Sigma-Aldrich) or 50µM BSA (equivalent to control condition). For insulin sensitivity experiments, cells were stimulated for 10min with 100nM insulin following siRNA transfection.

**Lipid droplet imaging**

After siRNA transfection and incubation of cells with 100µM oleate, HepG2 cells and primary rat hepatocytes were washed three times with ice-cold 1x PBS and fixed in 4% paraformaldehyde for 30min. LD were stained for 10min with Bodipy 493/503 (1µg/ml; Thermo Fisher Scientific). Fluorescence was visualized with a Nikon A1 confocal microscope. Each measurement of LD size and LD number per cell was obtained from over 240 cells (6 images per condition with at least 40 cells per image) using Image J software. Only particles falling in the 1 to 50µm range were considered for analysis.

For time-lapse confocal microscopy, siRNA-transfected HepG2 cells were incubated with 100µM oleate in the presence of 1µg/ml Bodipy 493/502 overnight at 37°C under 5% CO2. Z-stacks were acquired every 10min over a 10h period using a Nikon A1 confocal microscope in order to image whole cells. Video frames were analyzed with Image J software using the threshold function to outline Bodipy-labelled LD.

**Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)**

Total RNA from tissues and cells were extracted using the Trizol reagent (Thermo Fisher Scientific), according to manufacturer’s instructions. Total RNA (500ng) was reverse transcribed (SuperScript II reverse transcriptase; Thermo Fisher Scientific) and quantitative real-time PCR was performed using SYBR Green I Master Mix on a LightCycler 480 Real-Time PCR System (Roche Applied Science). Results are represented as arbitrary units indicating relative expressions based on the comparative Ct (ΔΔCt) method. Data were normalized using housekeeping genes *Cyclophilin A* (for mouse tissue) or *Hypoxanthine phosphoribosyltransferase 1 (HPRT1)*; for human cells,
and presented as fold changes relative to control samples.

**Immunohistochemistry**

HepG2 cells were fixed on slides with 4% paraformaldehyde for 30 min at RT. Fixed HepG2 cells, were blocked for one hour in 1x PBS containing 1.5% normal goat serum. Samples were incubated with anti-Seipin primary antibody (Santa Cruz Biotechnology, clone L-16; 1:50) overnight at 4°C before using the ImmunoCruz goat ABC staining system (Santa Cruz Biotechnology). Nuclei were stained with Hematoxylin Gill no°3 (Sigma-Aldrich).

**Immunofluorescence**

To study SCD1 and Seipin protein colocalization, HepG2 cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Cells were washed with PBS, blocked with 3% BSA in Tris-buffered saline containing 1% Triton X-100 and then incubated with anti-SCD1 (Abcam; mouse primary 1:200) and anti-Seipin (Santa Cruz Biotechnology, clone L-16; rabbit primary 1:50). Cells were washed with PBS and incubated with anti-mouse Alexa Fluor 488 and anti-rabbit Alexa Fluor 647 (Abcam; goat secondary 1:1000). The cells were washed with PBS and images acquired using a Nikon A1 confocal microscope fitted with a 100x oil immersion lens. For colocalization analysis, Pearson’s $r$ and Spearman’s $p$ correlation coefficients were obtained from over 200 cells (10 images with at least 20 cells per image) using the Coloc2 analysis plugin in ImageJ software.

**Immunoblot analysis**

After siRNA transfection and incubation with 100µM oleate, cells were lysed in RIPA buffer supplemented with cOmplete protease inhibitors and phosphatase inhibitor cocktail 3 (Sigma-Aldrich). Proteins were denatured at 95°C for 5 min, 30µg protein/lane was loaded onto SDS-PAGE and immunoblot analyses were carried out using the antibodies listed in Table 1. Protein extracts from rat testis, adipose tissue and primary
Hepatic Seipin depletion increases SCD1 activity and LD formation

hepatocytes, mouse livers as well as human hepatocyte-hepatocarcinoma HepG2 cells were probed with the anti-Seipin antibody (Santa Cruz Biotechnology, clone L-16; 1:50). *Image J* software was used to quantify band intensity.

**Lipid extraction and quantification using gas chromatography**

Cells transfected with siRNA (as well as corresponding controls) were trypsinized for 5min, collected and spun at 1200rpm for 5min to pellet hepatocytes. HepG2 cell pellets were washed in 1x PBS. Lipid extractions were conducted using previously described protocols [44, 45]. Samples were analyzed using a 7890B gas chromatography system (Agilent Technologies) with a flame ionization detector, and samples were separated on a J&W DBFFAP fused-silica capillary column (15m, 0.1µm film thickness, 0.1mm i.d.; Agilent Technologies). Fatty acid peaks were identified by comparison with retention times of fatty acid methyl ester standards. To estimate SCD1 activity, we calculated the product-to-precursor fatty acid ratio (i.e., 18:1n9/18:0 and 16:1n7/16:0), as previously reported [46, 47]. Fatty acid data were normalized to protein concentrations for each treatment condition and reported as µg fatty acid per µg/µl protein.

**Fatty acid uptake**

Uptake of [3H]oleate was measured in confluent HepG2 cells and rat primary hepatocytes as previously described [48, 49]. Briefly, 0.68µCi of [9,10-3H]oleic acid (54.6 Ci/mmol; Perkin Elmer) was mixed with 50µM of non-radioactive oleate (Sigma-Aldrich) and dissolved in a 173µM BSA solution free of fatty acids. Cells were incubated with this oleate/BSA solution for 10min at 37°C. Uptake was stopped by removal of the oleate/BSA solution followed by the addition of ice-cold 1x PBS (5ml) containing 200µM of phloretin and 0.1% BSA (wt/v). After a 2min incubation, cells were washed six times with ice-cold 1x PBS. Cells were then lysed with 2M NaOH and aliquots of the lysate were used for protein concentration and radioactivity measurements. Radioactivity was measured in a TRI Carb 2800TR liquid scintillation counter after the addition of 10ml Ultima-Gold (Perkin Elmer). Data were presented as number of counts per minute.
Hepatic Seipin depletion increases SCD1 activity and LD formation


**De novo lipogenesis**

*De novo* lipogenesis was evaluated by measuring the incorporation of $[^1]^{14}C$ acetate into lipids, as described previously [44, 50, 51]. Briefly, post-transfection cells were incubated with 1µCi of [1,2-$^{14}C$]acetic acid (54.3 Ci/mol; Perkin Elmer) for 4h. Cells were then suspended in 200µl 1x PBS and total cellular lipids were extracted in chloroform/methanol (2:1, v/v). The lipid extract was dried under nitrogen and reconstituted in 100µl hexane. Radiolabeled lipids were separated by thin layer chromatography on silica-coated plates using a hexane/diethyl-ether/acetic acid solution (80:20:1, v/v) as a developing solvent [44, 50, 51]. Lipids were visualized by exposure to iodine vapors and the bands corresponding to authentic lipid standards (FFA, TAG, DAG, CE, and PL) were scraped into separate vials. Radioactivity was measured and data presented as CPM of $^{14}C$ per µg of protein.

**Statistical analysis**

When evaluating statistical significance, we used a Student’s t-test (two-tailed) to compare two groups and a two-way analysis of variance (ANOVA) when more than one factor was evaluated. A p<0.05 was considered statistically significant. Unless specified otherwise, data are presented as mean ± SD.
Hepatic Seipin depletion increases SCD1 activity and LD formation

Results

Seipin is expressed in hepatocytes

Since Seipin as yet to be shown to play a cell autonomous role in the liver, our first aim was to confirm the presence of the Seipin protein in the various hepatic models used in this study. To this end, we performed antibody-based analyses in HepG2 cells (a human hepatocyte-hepatocarcinoma cell line) as well as in rat primary hepatocytes. The testis, a tissue known to express Seipin [52], was used as positive control. An anti-Seipin antibody (Table 1), detected a band of ~67kD in the rat testis and a major band at ~60kD in the rat adipose tissue, in agreement with previous observations [52]. Primary rat hepatocytes also showed a ~60kD band while HepG2 cells displayed a slightly higher band (~61kD), presumably reflecting the fact that human Seipin is 33 amino acids longer. The detected levels of Seipin were lower in adipocytes and hepatocytes compared to testis (Fig.1A, left panels). A ~60kD band detected in liver extracts of WT mice was absent in liver extracts of Bspl2−/− mice (Fig.1A, right panels), confirming antibody specificity. We used immunohistochemistry to expand and confirm these results. The Seipin protein was concentrated in the perinuclear space of HepG2 cells, a pattern consistent with ER localization (Fig.1B).

BSCL2 knockdown alters lipid droplet morphology and size

To evaluate the role of Seipin in vitro, primary rat hepatocytes and HepG2 cells were transfected with a siRNA designed to knockdown Bscl2/BSCL2. This approach decreased Seipin protein levels to 54% and 36% in HepG2 cells (Fig.1C, left panels) and primary rat hepatocytes (Fig.1C, right panels), respectively. Oleate treatment was then used to induce LD formation, increasing both number and size of the organelle (Fig.2A). Inhibition of Bscl2/BSCL2 expression increased the number (80% more) and the size (150% larger) of LD, irrespective of the presence of oleate, in both rat primary hepatocytes and HepG2 cells (Fig.2A). Live imaging of Seipin-deficient HepG2 cells showed greater LD clustering with at least partial LD fusion, resulting in aggregates of
abnormal morphology, and suggested increased LD persistence (Fig.2B). We analyzed mRNA expression levels of key genes implicated in LD homeostasis. In both HepG2 cells and the liver of Bsc12^{−/−} mice (Fig.3), a Seipin deficiency was associated with increased expression of Plin5/PLIN5 and Cidea/CIDEA; genes involved in LD formation and stability, respectively [53, 54]. In contrast, a decrease in Atgl/ATGL expression, a gene known to be involved in lipolysis [55-57], was observed in HepG2 cells and the liver of fasted Bsc12^{−/−} mice, but not in fed mice. Together, our data suggest that lowering Seipin levels in hepatocytes increased LD biogenesis.

**Alteration of lipid droplet homoeostasis following BSCL2 knockdown is concomitant with changes in lipid metabolism**

In order to better understand the mechanism underlying the observed increase in LD formation and expansion in Seipin-deficient cells (Fig.2), we evaluated fatty acid uptake by [$^{3}$H]oleate incorporation into HepG2 cells and primary rat hepatocytes following siRNA transfection. Bsc12/BSCL2 knockdown caused an increase in fatty acid uptake in both HepG2 cells and primary rat hepatocytes (40%; Fig.4A). In siRNA-transfected HepG2 cells, elevated fatty acid uptake was associated with increased levels of the PPARγ transcription factor (40%; Fig.4B, top panel) and at least one of its direct targets, the translocase CD36 implicated in fatty acid transport [58] (80%; Fig.4B, middle panel).

It has recently been shown that Seipin can have an effect on PPARγ nuclear localization and activity through an interaction with the TAG synthesis enzyme AGPAT2 [30]. We therefore investigated AGPAT2 levels in our siRNA-transfected cells. Interestingly, Seipin deficiency led to increased expression of AGPAT2 (40%; Fig.4B, bottom panel).

To determine if *de novo* lipogenesis was also affected by diminished Seipin levels, we measured [$^{14}$C]acetate incorporation into lipids of siRNA-transfected hepatic cells. A 25% increase in the synthesis of total lipids was observed in HepG2 cells transfected with BSCL2 siRNA (Fig.5A, top panel). This higher overall synthesis was primarily due to increased synthesis of TAG and DAG (22% and 28% respectively; Fig.5A, bottom panels). No difference was observed in the other lipid fractions examined, such as free fatty acids, ceramides and cholesterol esters (data not shown). In siRNA-transfected
HepG2 cells, elevated *de novo* lipogenesis was also associated with increased expression of several lipogenic enzymes such as ACC, FAS and SCD1, as well as the transcription factor SREBP-1c (Fig.5B). In addition, an increase in mature SREBP-1c protein levels was observed in the liver of *Bscl2*−/− mice (Fig.5C). Interestingly, we also showed a decrease in the expression of proteins implicated in lipolysis [55-57] and β-oxidation [59, 60] (ATGL and PPARα, respectively) (Fig.5B, bottom panels), suggesting that inhibition of β-oxidation may contribute to the LD alterations observed in Seipin-deficient cells.

**Seipin and SCD1 have opposing effect on LD formation and lipid synthesis**

We showed an induction of SCD1 expression in Seipin-deficient cultured hepatocytes (Fig.5B). A similar result was reported in the liver of *Bscl2*−/− mice [8]. The mostly perinuclear pattern of expression observed for both SCD1 and Seipin is consistent with the expected localization of these two ER-resident proteins. We determined that SCD1 and Seipin colocalize in HepG2 cells (Pearson’s *r* value: 0.63, Spearman's *p* value: 0.47; Fig.6A), hinting to a possible functional relationship between these two proteins. We therefore tested the effect of *SCD1* deficiency in HepG2 cells using a validated siRNA (Fig.6B). Co-transfection of *SCD1* and *BSCL2* siRNA rescued the Seipin deficiency phenotype, i.e., the number and size of LD was close to normal when compared to cells transfected with *BSCL2* siRNA alone, irrespective of the presence or absence of oleate (Fig.6C). The increase in fatty acid uptake (Fig.6D) and *de novo* lipogenesis (Fig.6E) observed in Seipin-deficient HepG2 cells was also lost when cells were co-transfected with *SCD1* and *BSCL2* siRNA. Co-transfected cells exhibited a low lipid uptake and synthesis profile closer to that of cells transfected with *SCD1* siRNA alone. In a similar fashion, we found that the MUFA/SFA ratio is higher in Seipin-deficient hepatocytes compared to non-transfected control HepG2 cells, whereas it tended to be lower in SCD1-deficient or co-transfected cells (Fig.6F). Together, these observations show that Seipin and SCD1 have opposing effects on LD formation and lipid synthesis, and suggest that Seipin’s effect on hepatic lipid synthesis/accumulation is mediated by SCD1.

**Seipin deficiency increases basal phosphorylation of insulin-signaling proteins**
General insulin resistance and hyperglycemia are characteristic of patients with BSCL2 [5, 17, 61], as well as BscI-/ mice [7-9]. We therefore evaluated the expression level and the phosphorylation state of key proteins involved in the insulin-signaling cascade. Seipin deficiency was associated with increased phosphorylation of AKT (both Ser473 and Thr308 sites), ERK1/2, mTOR and P70S6K in HepG2 cells stimulated or not by insulin (Fig.7A). The levels of AKT (Ser473) and IRS1 (Tyr612) phosphorylation were also increased in liver extracts of BscI-/ mice (Fig.7B). In accordance with an increase in the phosphorylation of insulin-signaling proteins, we noted that, in BscI-/ mice, the expression of glucose metabolism markers such as Gck was increased while G6pc expression was decreased. Unexpectedly, Pepck expression was increased (Fig.7C).

We then analyzed the effect of BSCL2 knockdown on physiological responses activated by insulin. We stimulated siRNA-transfected rat primary hepatocytes with insulin and measured both fatty acid uptake and de novo lipogenesis. In accordance with initial observations (Figs.4&5), Seipin deficiency increased both fatty acid uptake and lipogenesis. However, the presence of insulin further stimulated fatty acid uptake (25% compared to BSCL2 siRNA-transfected cells without insulin) (Fig.7D) and de novo lipogenesis (35% total lipids, compared to BSCL2 siRNA-transfected cells without insulin) (Fig.7E). As previously observed (Fig.5A), increased de novo lipogenesis primarily stemmed from increased TAG and DAG synthesis (Fig.7E), as the levels of others lipid classes did not vary (data not shown). These data suggest that in cases of Seipin deficiency, hepatic lipid uptake and synthesis as well as gluconeogenesis are increased, probably aggravating the BSCL2 phenotype and contributing to hepatic dysfunction.

Seipin deficiency increases the expression of ER stress markers

ER stress and the unfolded protein response (UPR) are critically involved in the initiation of many diseases, such as the metabolic syndrome [40, 62, 63]. In addition, this pathway has been reported to play an important role in LD formation and lipogenesis promotion in the liver [39, 64]. To determine if Seipin deficiency could induce ER stress, we measured the mRNA levels of key genes implicated in this process. In BSCL2 siRNA-transfected
Hepatic Seipin depletion increases SCD1 activity and LD formation

HepG2 cells, *ATF4* and *GRP78* mRNA expression was increased by a little over 50% and *CHOP* by 100% ([Fig. 8A](#)). PERK protein levels were also increased by 34% and 27% in *BSCL2/Bscl2* siRNA-transfected HepG2 cells as well as primary rat hepatocytes, respectively ([Fig. 8B](#)). Our study revealed that Seipin deficiency induces expression of several markers of ER stress.
Discussion

In this study, we first confirmed that B scl2 is expressed in mouse liver (Fig.1A) albeit at a low protein level relative to testis, as previously reported for mRNA [65]. One group was recently able to detect the Seipin protein in human liver using LC/MS (humanproteomemap.org; [66]). We used siRNA to lower Seipin protein levels in hepatocytes (Fig.1C). This induced an increase in the number and the size of LD (Fig.2A). We also observed LD aggregation defects (Fig.2B), implying that Seipin plays a role in the generation, expansion and morphology of LD. These observed changes in shape and number of LD are similar to reported results in yeast, where a depletion of the BSCL2 yeast ortholog SEI1/FLD1 led to LD with irregular shapes and sizes [19, 21, 22, 24]. Up to 30% of the SEI1/FLD1 deletion mutants contained one or a few supersized LD and about 60% of them contained an amorphous aggregation of LD [19].

Seipin has been suggested to act as a scaffold protein [30], however its function remains unclear. Seipin and SCD1 proteins are both localized in the ER [67, 68], and colocalize significantly in HepG2 cells (Fig.6A). Moreover, Seipin and SCD1 have opposite effects on LD homeostasis (Fig.6C). Taken together, our results suggest that Seipin and SCD1 are part of an ER-resident protein complex that controls LD formation. Different models for LD biogenesis consistently suggest that LD emerge from the ER [69]. The most accepted model posits that the accumulation of TAG between the bilayer leaflets of the ER membrane drives the genesis of nascent LD [28, 29]. In accordance with this, LD have been localized in close proximity to or even tethered to the ER in yeast [70, 71].

Seipin deficiency in hepatocytes caused lipid accumulation and was associated with increased expression of CHOP, GRP78, ATF4 and the protein PERK (Fig.8), four markers of the unfolded protein response (UPR) to ER stress. A similar consequence of Seipin deficiency was previously observed in neuronal cells [72, 73]. In these prior studies, loss-of-function mutations in the Seipin protein induced a “seipinopathy”, a motor neuron disease associated with high LD formation and TAG storage as well as ER stress [74]. Interestingly, an activation of the UPR (PERK-eIF2α-ATF4) pathway, like the one seen in our in vitro models (Fig.8), can activate the expression of several
lipogenic genes \((\text{Accl/ACC, Fas/FAS, Scd1/SCD1})\) and the associated transcription factor SREBP-1c \([11, 33, 35-37]\), thereby accentuating hepatic lipid synthesis/storage and potentially aggravating a nascent hepatic steatosis \([33, 35, 37, 38]\).

The presence of smaller than normal LD in \(C.elegans\ fat-6:\text{fat-7}\) double mutants lacking most desaturases \([75]\) suggests SCD activity is required for LD expansion. The MUFA/SFA intracellular lipid ratio also seems to play an important role in LD homeostasis, most notably on fusion and growth \([76]\). This is consistent with a role for SCD1, an enzyme that converts SFA into MUFA, in LD biogenesis and, by extension, TAG storage. For example, an increase in LD size within 3T3-L1 preadipocyte cells is associated with an increase in SCD1 expression and MUFA/SFA ratio \([76]\). The increase in SCD1 expression (Fig.5B) following our \(BSCL2\) knockdown was concomitant with an increase in the MUFA/SFA ratio (hence SCD1 activity; Fig.6F) and TAG synthesis (Figs.5A and 7E).

Moreover, high \(Scd1\) expression activates de novo lipogenesis via an elevation in hepatic SREBP-1c levels \([77]\) that consequently increases the expression of lipogenic genes, including \(Scd1\) itself. The potential therefore exists for a reinforcing feedback loop to be established, leading to \(Scd1\) overexpression and enhancing hepatic lipogenesis following Seipin deficiency (Fig.5). Underlying the important role of SCD1 in TAG metabolism, DGAT (key enzymes implicated in TAG synthesis) colocalize with SCD1 in the ER \([78]\) and could have synergistic interactions with Seipin \([26]\). The increase in number and size of LD we observed following \(BSCL2\) knockdown (Figs.2A&6C) could be due to lipid metabolism changes secondary to an increase in SCD1 activity. In agreement with this hypothesis, 3T3-L1 preadipocyte cells bearing a \(Bscl2\) mutation, and presumably possessing increased SCD1 activity, exhibit enhanced TAG synthesis \([25]\). Overall, increased SCD1 activity appears sufficient to explain most of the observed effects on fatty acid metabolism following \(Bscl2/BSCL2\) knockdown, including elevated PPAR\(\gamma\) expression and CD36-mediated fatty acid uptake (Fig.4). In accordance with this, a \(SCD1\) knockdown reversed the effect of Seipin deficiency on LD formation (Fig.6C) and on lipid metabolism (Fig.6D,E) in hepatocytes. Inhibition of SCD1 activity is known to decrease PPAR\(\gamma\) expression \([79]\). As CD36, the key cell surface receptor that facilitates
hepatic fatty acid uptake, is a direct transcriptional target of PPARγ [58], it is not surprising that SCD1 deficiency alone decreases oleate uptake (Fig. 6D).

Recent studies have shown that the adipose tissue plays a major role in the establishment of hepatic steatosis in B scl2−/− mice [7, 9, 15]. Expressing Seipin in adipose tissue alone is sufficient to rescue lipodystrophy, hepatic steatosis and insulin resistance in B scl2−/− mice [15]. Chen and collaborators also reported that mice with a specific hepatic deletion of Seipin (B scl2Li−/−) did not show increased lipid deposition in the liver on a standard chow diet [80]. Such striking results led these researchers to conclude that Seipin does not play a role in hepatic steatosis. However, our study clearly shows an effect of Seipin deficiency on fat accumulation in hepatocytes. The discrepancy between these in vivo results and our observations is probably due to the storage of circulating lipids, in the form of free or esterified fatty acids in the blood, within the adipose tissue. In B scl2−/− mice, the absence of adipose tissue causes an accumulation of plasma fatty acids and a compensatory fatty acid uptake (leading to steatosis) in the liver. Consequently, B scl2−/− mice do not suffer from hypertriglyceridemia [7, 8]. B scl2Li−/− mice possess a normal adipose tissue that stores excess fat originating from a standard chow diet. However, a high fat diet leads to a strong increase in circulating lipid levels, and under these conditions both B scl2Li+/− and B scl2Li−/− mice develop hepatic steatosis [80]. Presumably, the storage capacity of both the adipose tissue and the liver becomes saturated in these mice, precluding the observation of more subtle intracellular differences. Consistent with a cell autonomous role for Seipin in hepatic fat accumulation, we show that the expression of several genes implicated in LD homeostasis is elevated in the liver of B scl2−/− mice (Plin5 and Cidea; Fig. 3). Seipin does not appear to be necessary for the formation of a LD, notably in B scl2/BLSC2−/− hepatocytes, but this does not exclude a role in lipid storage. In support of such a role, Yang et al. have suggested that Seipin restricts lipogenesis and LD accumulation in non-adipocyte cells [27]. The authors show that Seipin overexpression inhibits ectopic lipid-induced LD formation in a mouse hepatocyte cell line (AML-12 cells) and distinguish two functions for the Seipin protein, one in adipocyte maturation (via its C-terminal domain) and another in the control of intracellular lipid levels (via a conserved core sequence) in non-adipocyte cells [27]. Therefore, we argue that the endogenously expressed Seipin protein plays a role in LD
homeostasis and TAG storage in hepatocytes.

Several previous studies have clearly demonstrated that Seipin deficiency in both mice and humans leads to insulin resistance [7-9]. Surprisingly, we observed that Seipin deficiency increased basal phosphorylation of AKT, ERK and P70S6K proteins, suggesting an increase in insulin sensitivity (Fig.7A). In agreement with this interpretation, Chen and collaborators observed improved hepatic insulin signaling in BscI2−/− mice, as measured by insulin clamp [16]. To explain their result, the authors suggest that the enhanced insulin sensitivity observed after 16h fasting stems from increased levels of insulin receptors and downstream signaling effectors such as IRS1 and AKT [16]. The increased basal phosphorylation of insulin signaling pathway proteins observed in our BSCL2 siRNA-transfected hepatocytes may be explained, at least in part, by the effect of Seipin deficiency on SCD1 activity (Fig.6F), as an increase in MUFA has been shown to stimulate insulin signaling [81-85].

Insulin negatively regulates the expression of gluconeogenic genes Pepck and G6pc, and increases expression of Gck, the enzyme responsible for the first step of hepatic glycolysis [86]. The modulation of glucose metabolism markers observed in our study (Fig.7C) is somewhat consistent with an activation of the insulin signaling proteins following Seipin deficiency, with the notable exception of Pepck gene expression being specifically elevated in fasted mice. This paradox might be explained by the activation of ER stress in Seipin deficient hepatocytes (Fig.8). PEPCK expression is activated by ER stress through promoter binding by the ATF4 transcription factor, leading to increased transcription [87]. Additionally, Pepck expression could enhance gluconeogenesis in Seipin deficient cells, leading to increased intracellular glucose concentration and the reduction of AMPK phosphorylation we observe (Fig.7B) [88, 89]. Interestingly, decreased AMPK phosphorylation/activity can also lead to an activation of its targets proteins, notably the lipogenic enzyme ACC [90]. Therefore, a combined increase in gluconeogenesis and insulin signaling can lead to further activation of lipogenic markers such as FAS, SCD1 and ACC (Fig.5) [91-97].

We showed that Seipin depletion in cultured hepatocytes leads to an increase in LD number and size. These changes in LD homeostasis are probably due to an upregulation
of lipid metabolism, characterized by an increase in SCD1 activity leading to a higher MUFA/SFA ratio. In accordance with this, a SCD1 knockdown reversed the LD formation defects and the changes in lipid metabolism homeostasis associated with Seipin depletion. Interestingly, Seipin and SCD1 also colocalize, leading us to propose a functional interaction within the ER membrane whereby Seipin controls lipid metabolism and storage through SCD1 activity and LD formation.
**Acknowledgements**

We wish to thank Dr. Jocelyne Magre (University of Nantes, France) for kindly providing us with mRNA and protein extracts from Bsc12−/− mice, as well as Dr. Xiaqin Ye (University of Georgia, USA) for samples of Bsc12−/− mouse liver. We also thank Denis Flipo for his precious help with confocal microscopy, the laboratory of Dr. Diana Averill for primary rat hepatocytes and Dr. Daniel Boismenu for his help with data analysis and discussion.

The Discovery Grants Program of the National Science and Engineering Research Council of Canada (NSERC) funded this research. MAL and SL were supported by the Fond de Recherche du Québec-Nature et Technologie (FRQNT) fellowships.

**Conflict of Interest**

The authors declare that they have no competing interests.
References


Hepatic Seipin depletion increases SCD1 activity and LD formation

Table 1. List of antibodies used for immunoblotting

<table>
<thead>
<tr>
<th>Antibody target</th>
<th>Manufacturer</th>
<th>Catalog number</th>
<th>Concentration used</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACC</td>
<td>Cell Signaling Tech.</td>
<td>3662</td>
<td>1: 1000</td>
</tr>
<tr>
<td>AGPAT2</td>
<td>Abcam</td>
<td>ab62599</td>
<td>1: 500</td>
</tr>
<tr>
<td>AKT</td>
<td>Cell Signaling Tech.</td>
<td>9272</td>
<td>1: 1000</td>
</tr>
<tr>
<td>AMPK α</td>
<td>Cell Signaling Tech.</td>
<td>2532</td>
<td>1: 1000</td>
</tr>
<tr>
<td>ATGL</td>
<td>Cayman Chemical</td>
<td>10006409</td>
<td>1: 1000</td>
</tr>
<tr>
<td>β-Actin</td>
<td>Cell Signaling Tech.</td>
<td>4970</td>
<td>1: 1000</td>
</tr>
<tr>
<td>BSCL2/Seipin</td>
<td>Santa Cruz Biotech.</td>
<td>sc-55987</td>
<td>1: 200</td>
</tr>
<tr>
<td>CD36</td>
<td>Abcam</td>
<td>ab78054</td>
<td>1: 1000</td>
</tr>
<tr>
<td>ERK1/2</td>
<td>Cell Signaling Tech.</td>
<td>9103</td>
<td>1: 1000</td>
</tr>
<tr>
<td>FAS</td>
<td>Santa Cruz Biotech.</td>
<td>sc-55580</td>
<td>1: 1000</td>
</tr>
<tr>
<td>GAPDH</td>
<td>Cell Signaling Tech.</td>
<td>5174</td>
<td>1: 1000</td>
</tr>
<tr>
<td>IRS1</td>
<td>Cell Signaling Tech.</td>
<td>2382</td>
<td>1: 1000</td>
</tr>
<tr>
<td>p-AKT (Thr 308)</td>
<td>Cell Signaling Tech.</td>
<td></td>
<td>1: 1000</td>
</tr>
<tr>
<td>p-AKT (Ser 473)</td>
<td>Cell Signaling Tech.</td>
<td>4060</td>
<td>1: 1000</td>
</tr>
<tr>
<td>p-AMPKα (Thr 172)</td>
<td>Cell Signaling Tech.</td>
<td>2535</td>
<td>1: 1000</td>
</tr>
<tr>
<td>p-ERK1/2 (Thr 202/Tyr 204)</td>
<td>Cell Signaling Tech.</td>
<td>4370</td>
<td>1: 1000</td>
</tr>
<tr>
<td>p-IRS1 (Tyr 612)</td>
<td>Santa Cruz Biotech.</td>
<td>sc-17195-R</td>
<td>1: 1000</td>
</tr>
<tr>
<td>p-P70S6K (Thr389)</td>
<td>Cell Signaling Tech.</td>
<td>9234</td>
<td>1: 1000</td>
</tr>
<tr>
<td>P70S6K</td>
<td>Cell Signaling Tech.</td>
<td>9202</td>
<td>1: 1000</td>
</tr>
<tr>
<td>PERK</td>
<td>Cell Signaling Tech.</td>
<td>3192</td>
<td>1: 1000</td>
</tr>
<tr>
<td>PPARα</td>
<td>Santa Cruz Biotech.</td>
<td>sc-9000</td>
<td>1: 1000</td>
</tr>
<tr>
<td>PPARγ</td>
<td>Cell Signaling Tech.</td>
<td>2435</td>
<td>1: 1000</td>
</tr>
<tr>
<td>SCD1</td>
<td>Abcam</td>
<td>ab19862</td>
<td>1: 1000</td>
</tr>
<tr>
<td>SREBP-1</td>
<td>Santa Cruz Biotech.</td>
<td>sc-366</td>
<td>1: 1000</td>
</tr>
<tr>
<td>α-Tubulin</td>
<td>Cell Signaling Tech.</td>
<td>2144</td>
<td>1: 1000</td>
</tr>
<tr>
<td>goat IgG (HRP-linked)</td>
<td>Santa Cruz Biotech.</td>
<td>sc-2020</td>
<td>1: 1000</td>
</tr>
<tr>
<td>mouse IgG (HRP-linked)</td>
<td>Cell Signaling Tech.</td>
<td>7076</td>
<td>1: 1000</td>
</tr>
<tr>
<td>rabbit IgG (HRP-linked)</td>
<td>Cell Signaling Tech.</td>
<td>7074</td>
<td>1: 1000</td>
</tr>
</tbody>
</table>
Hepatic Seipin depletion increases SCD1 activity and LD formation

**Figure Legends**

**Figure 1. Seipin expression in hepatocytes**

(A) Seipin expression was evaluated by Western blot in protein extracts prepared from rat testis, rat adipose tissue (AT), primary rat hepatocytes and HepG2 cells (left panels), as well as liver of WT and Bscl2−/− mice (right panels). GAPDH or α-Tubulin were used as loading controls. Tissues from 3 different animals or from 3 different cell passages were tested (n=3). (B) Immunohistochemical staining for Seipin (brown color) in HepG2 cells was followed by nucleus counterstaining (blue). A negative control without primary antibody is presented for comparison. The images are representative of three different cell experiments (n=3). Bar: 100µm. (C) Seipin expression was evaluated by Western blot in HepG2 cells (left panels) and rat primary hepatocytes (right panels) transfected with a Bscl2 siRNA (siBSCL2) or a negative control (CTRL). Protein levels evaluated by densitometry were normalized against GAPDH (loading control) and negative controls. Graphs combine results from 5 independent experiments (n=5). ** p<0.002. *** p<0.001.

**Figure 2. Seipin deficiency affects LD formation, expansion and aggregation**

(A) Rat primary hepatocytes and HepG2 cells were transfected with negative control (CTRL) or Bscl2 siRNA (siBSCL2), and treated (or not) with 100µM oleate for 24h. Cells were stained with Bodipy 493/503 to allow quantification of LD number and size. Bars: 100 µm. Graphs combine results from 5 independent experiments (n=5). Results are presented for number and size of LD as number of LD per 100 cells and diameter of LD (µm), respectively. * p<0.05. ** p<0.002. *** p<0.001. (B) Time-lapse analysis of LD formation in control and Seipin-deficient HepG2 cells. Cells were transfected with negative control (CTRL) or BSCL2 siRNA (siBSCL2), incubated with 100µM oleate and Bodipy 493/502 and imaged by confocal microscopy in a 37°C chamber supplied with 5% CO₂. Images were taken every 10min over a period of 16.5h. T=0 in figures corresponds to hour 14 of the time-lapse.Outlined in blue: LD expansion/persistence,
red: LD aggregation, yellow: LD degradation. Images are representative of five different experiments (n=5). Bar: 35µm.

**Figure 3. Seipin deficiency modulates expression of LD biogenesis genes**

Expression of genes involved in LD formation and stability, as well as lipolysis, was evaluated by qRT-PCR in HepG2 cells transfected overnight with negative control (CTRL) or BSCL2 siRNA (siBSCL2), and in the liver of wildtype (WT) and Bscl2<sup>-/-</sup> (KO) mice fasted for 24h or fed ad libitum. Results were normalized against HPRT1 or Cyclophilin A (CYCLO) and negative controls where appropriate. Graphs combine results from 5 independent experiments (HepG2 cells) or 5 different liver extracts obtained from Bscl2<sup>-/-</sup> mice (n=5). * p<0.05. ** p<0.002. *** p<0.001. **** p<0.0001. NS: not significant.

**Figure 4. Seipin deficiency increases fatty acid uptake in hepatocytes**

(A) HepG2 cells and rat primary hepatocytes were transfected with negative control (CTRL) or BSCL2 siRNA (siBSCL2) and incubated with [3H]oleate for 10min. Incorporated radioactivity was measured in cell lysates, normalized against negative controls and presented as CPM/mg of total protein. Graphs combine results from 5 independent experiments (n=5). (B) HepG2 cells were transfected with negative control (CTRL) or BSCL2 siRNA (siBSCL2), and Western blot analyses were performed to measure the expression of proteins involved in fatty acid uptake (PPARγ and CD36). The expression level of AGPAT2, implicated in the PPARγ signaling pathway, is also presented. Protein levels evaluated by densitometry were normalized against GAPDH (loading control) and negative controls. Graphs combine results from 5 independent experiments (n=5). * p<0.05. ** p<0.002. *** p<0.001.

**Figure 5. Seipin deficiency increases de novo lipogenesis in hepatocytes**

(A) HepG2 cells were transfected with negative control (CTRL) or BSCL2 siRNA (siBSCL2) and incubated with [14C]acetate for 4h. Incorporated radioactivity was
measured in extracted total lipids, triglycerides and diacylglycerol, and presented as CPM/mg of total protein. Graphs combine results from 5 independent experiments (n=5). (B) Expression of proteins involved in lipid metabolism (ACC, FAS, mature SREBP-1c, SCD1, ATGL and PPARα) was measured by Western blot in HepG2 cells transfected with negative control (CTRL) or BSCL2 siRNA (siBSCL2). Protein levels evaluated by densitometry were normalized against GAPDH and negative controls. Graphs combine results from 5 independent experiments (n=5). (C) Expression of mature SREBP-1c was also measured in liver extracts from wildtype (WT) and Bsl2–/– (KO) mice fasted for 24h or fed ad libitum. Protein levels evaluated by densitometry were normalized against β-Actin. Graph combines results from 5 different liver extracts (n=5). * p<0.05. ** p<0.002. *** p<0.001.

Figure 6. SCD1 knockdown reverses the phenotype observed in Seipin-deficient hepatocytes

(A) Confocal images of HepG2 cells showing staining for Seipin/BSCL2 (red), SCD1 (green) and cell nuclei (DAPI; blue). Merged (and zoom) image shows sites of colocalization (yellow). Images are representative of five different experiments (n=5). Bar: 35µm. (B) SCD1 expression in protein extracts prepared from HepG2 cells transfected with a SCD1 siRNA (siSCD1) or a negative control (CTRL) were evaluated by Western blot. Protein levels evaluated by densitometry were normalized against GAPDH and negative control. Graph combines results from 5 independent experiments (n=5). (C) HepG2 cells were transfected with negative control (CTRL), SCD1, BSCL2, or cotransfected with both SCD1 and BSCL2 siRNA. Cells were then treated (or not) with 100µM oleate for 24h. Cells were stained with Bodipy 493/503 to allow quantification of LD number and size. Bar: 100µm. Graphs combine results from 5 independent experiments (n=5). Results are presented for number and size of LD as number of LD per 100 cells and diameter of LD (µm), respectively. (D) HepG2 cells were transfected with negative control (CTRL), SCD1, BSCL2, or with both SCD1 and BSCL2 siRNA. Cells were incubated with [3H]oleate for 10min. Incorporated radioactivity was measured in cell lysates, normalized against negative controls and presented as CPM/mg of total
protein. Graphs combine results from 5 independent experiments (n=5). (E) HepG2 cells were transfected with negative control (CTRL), SCD1, BSCL2, or with both SCD1 and BSCL2 siRNA(s). Cells were incubated with [14C]acetate for 4h. Incorporated radioactivity was measured in extracted total lipids, triglycerides and diacylglycerol, and presented as CPM/mg of total protein. Graphs combine results from 5 independent experiments (n=5). (F) The total SFA (16:0 and 18:0) and MUFA (16:1n7 and 18:1n9) cellular content of HepG2 cells transfected with negative control (CTRL), SCD1, BSCL2 or cotransfected with both SCD1 and BSCL2 siRNA was determined by gas chromatography. The results of 5 independent experiments (n=5) are presented as mean ± SEM and compared to CTRL for statistical analyses. * p<0.05. ** p<0.002. *** p<0.001.

Figure 7. Seipin deficiency increases basal phosphorylation of insulin-signaling proteins

(A) HepG2 cells were transfected with negative control (CTRL) or BSCL2 siRNA (siBSCL2) and incubated with 100nM insulin for 10min. AKT, ERK, mTOR and P70S6K protein expression as well as their phosphorylation states were evaluated by Western blot densitometry. Phosphorylated protein levels were normalized against total protein levels. Graphs combine results from 5 independent experiments (n=5). (B) AKT, IRS1 and AMPK protein expression levels and phosphorylation states were evaluated by Western blot densitometry in liver extracts from wildtype (WT) and Bsc/−/− (KO) mice fasted for 24h or fed ad libitum. Phosphorylated protein levels were normalized against total protein levels. Graphs combine results from 5 different liver extracts (n=5). (C) Expression of genes involved in glucose metabolism (Pepck, Gck and G6pc) was measured by qRT-PCR in the liver of wildtype (WT) and Bsc/−/− (KO) mice fasted for 24h or fed ad libitum. Results were normalized to Cyclophilin A (CYCLO). Graphs combine results from 5 different liver extracts (n=5). KO results were compared to WT for statistical analyses. (D) HepG2 cells were transfected with negative control (CTRL) or BSCL2 siRNA (siBSCL2). Cells were then incubated with [3H]oleate for 10min in the presence or absence of 100nM insulin. Incorporated radioactivity was measured in cell lysates, normalized against non-stimulated negative control and presented as CPM/mg of
Hepatic Seipin depletion increases SCD1 activity and LD formation

total protein. Graph combines results from 5 independent experiments (n=5). (E) HepG2 cells were transfected with negative control (CTRL) or BSCL2 siRNA (siBSCL2) and incubated with [14C]acetate for 4h in the presence or absence of 100nM insulin for the last 10min. Incorporated radioactivity was measured in extracted total lipids, triglycerides and diacylglycerol, and presented as CPM/mg of total protein. Graphs combine results from 5 independent experiments (n=5). * p<0.05. ** p<0.002. *** p<0.001. **** p<0.0001. NS: not significant.

Figure 8. Seipin deficiency increases the expression of ER stress markers

(A) Expression of genes involved in ER stress (ATF4, GRP78 and CHOP) was measured by qRT-PCR in HepG2 cells transfected with negative control (CTRL) or BSCL2 siRNA (siBSCL2). Results were normalized against HPRT1 and negative controls. Graphs combine results from 5 independent experiments (n=5). (B) PERK expression was measured by Western blot in HepG2 cells and primary rat hepatocytes transfected with negative control (CTRL) or BSCL2/Bscl2 siRNA (siBSCL2). Protein levels evaluated by densitometry were normalized against α-Tubulin and negative controls. Graphs combine results from 5 independent experiments (n=5). * p<0.05. ** p<0.002.
**A**

For Peer Review

![Western Blot Image]

**B**

**HepG2 Cells**

- No Antibody
- BSCL2 Antibody

![Cell Images with Antibodies]

**C**

**HepG2 cells**

<table>
<thead>
<tr>
<th>CTRL</th>
<th>siBSCL2</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEIPIN</td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
</tr>
</tbody>
</table>

**Rat primary hepatocytes**

<table>
<thead>
<tr>
<th>CTRL</th>
<th>siBsc12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seipin</td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
</tr>
</tbody>
</table>

![Bar Graphs]

**Mice Livers extracts**

<table>
<thead>
<tr>
<th>WT</th>
<th>Bscl2 KO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seipin</td>
<td></td>
</tr>
<tr>
<td>αTubulin</td>
<td></td>
</tr>
</tbody>
</table>

![Bar Graphs]
A

**Rat primary hepatocytes**

CTRL  siBcl2

- Oleate  

+ Oleate  

**HepG2 cells**

CTRL  SiBCL2

- Oleate  

+ Oleate  

---

![Image of fluorescence microscopy images showing LDs in hepatocytes](image)

**B**

**CTRL**

- T=0
- 10min
- 30min
- 40min
- 1h00min
- 1h10min
- 1h30min
- 1h40min

**siBSCL2**

- T=0
- 10min
- 30min
- 40min
- 1h00min
- 1h10min
- 1h30min
- 1h40min
A  
**HepG2 cells**

**Total lipids**

![Graph showing total lipids for HepG2 cells with comparisons between CTRL and BBScL2](image)

**Triglycerides**

![Graph showing triglycerides for HepG2 cells with comparisons between CTRL and BBScL2](image)

**Diacylglycerols**

![Graph showing diacylglycerols for HepG2 cells with comparisons between CTRL and BBScL2](image)

B  
**HepG2 cells**

![Western blot analysis of ACC and FAS with comparisons between CTRL and BBScL2](image)

![Western blot analysis of SREBP-1c and SCD1 with comparisons between CTRL and BBScL2](image)

![Western blot analysis of ATGL and PPARα with comparisons between CTRL and BBScL2](image)

C  
**Bscl2-/− Mice**

![Western blot analysis of SREBP-1c, β-Actin, ATGL, and PPARα with comparisons between WT and KO](image)

**FASTED**

![Description of western blots and comparisons between WT and KO](image)

**FED**

![Description of western blots and comparisons between WT and KO](image)
**HepG2 cells**

For Peer Review

E

**HepG2 cells**

Total lipids

Triglycerides

Diacylglycerols

F

**HepG2 cells**
**C**

Graphs showing mRNA levels of various genes in WT fasted, KO fasted, WT fed, and KO fed conditions.

**D**

*HepG2 cells*

**Fatty acids uptake**

Bar graph showing fatty acid uptake with controls (CTRL) and siBSCL2 conditions with and without insulin (INSULIN).

**E**

*Total lipids*

*Triglycerides*

*Diacylglycerols*

Bar graphs illustrating the incorporation of [1-^{14}C]acetate into lipids with and without insulin.
**A**

**HepG2 cells**

![Graph showing mRNA levels of ATF4/HPRT, GRP78/HPRT, and CHOP/HPRT in HepG2 cells under CTRL and siBSCL2 conditions.](image)

**B**

**HepG2 cells**

![Western blot images of PERK and α-TUBULIN in HepG2 cells under CTRL and siBSCL2 conditions.](image)

**Primary hepatocytes**

![Western blot images of PERK and α-TUBULIN in primary hepatocytes under CTRL and siBSCL2 conditions.](image)